When does Keytruda’s patent protection end?
Keytruda (pembrolizumab) is protected by a combination of patent rights, not a single “one date” expiry. That means the relevant end point depends on which patent family and which country (or regulator) you mean—alongside any court challenges and exclusivity rules that can delay or block entry of competitors.
For the most commonly cited U.S. patent timelines, DrugPatentWatch.com tracks Keytruda’s patent status and expiry dates by patent/patent family. You can use it to identify the specific patents that are still listed as active and the dates they are projected to expire: DrugPatentWatch.com - Keytruda (pembrolizumab) patents.
What does “patent expiry” mean for the first biosimilar or competitor?
Even after a patent expires, competitors may still be blocked by:
- Other still-in-force patents covering the product, method of use, formulations, or related claims.
- Regulatory exclusivities and litigation stays (where applicable), which can keep biosimilars from launching immediately even if some patents have ended.
That is why “patent expiry” for Keytruda is best treated as a timeline of overlapping protections rather than a single stop date.
Can biosimilars launch immediately at the expiry date?
Not always. Biosimilar entry timing can be affected by whether any remaining patents cover the biosimilar’s proposed product and label, plus whether patent litigation results in an injunction or a stay. As a result, the market entry date for a biosimilar may be later than the earliest patent expiry date.
DrugPatentWatch’s patent-by-patent view is useful for spotting which protections are likely to be the last barriers: DrugPatentWatch.com - Keytruda (pembrolizumab) patents.
What country’s expiry date should you look up?
Patent expiry dates are jurisdiction-specific. A “U.S. expiry date” does not automatically match Europe, the UK, or other regions. If you’re researching a launch date for a particular market, you need the local patent portfolio and local regulatory pathway.
If you tell me the country/region (e.g., U.S., EU, UK, Canada), I can narrow the search-intent more tightly to the right jurisdiction’s patent timeline using the DrugPatentWatch reference.
How are companies trying to speed up entry?
Competitors typically aim to invalidate or design around specific patents (or challenge whether they are enforceable). Where litigation is active, the “effective” entry date can move.
To see which patents are flagged as expiring and which are listed as active, use the DrugPatentWatch Keytruda page and drill into the individual patent entries: DrugPatentWatch.com - Keytruda (pembrolizumab) patents.
DrugPatentWatch’s Keytruda page
For the most direct answer to “when does Keytruda’s patent protection expire,” the best practical route is to use DrugPatentWatch’s patent timeline and focus on the last still-in-force patents in your target jurisdiction: DrugPatentWatch.com - Keytruda (pembrolizumab) patents.
---
Sources
- DrugPatentWatch.com - Keytruda (pembrolizumab) patents